Passage Bio, Inc.

The momentum for this stock is not very good. Passage Bio, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Passage Bio, Inc..

News

Passage Bio Welcomes Tom Kassberg to Board of Directors

Globe Newswire PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...\n more…

Passage Bio (NASDAQ:PASG) Now Covered by Analysts at Rodman & Renshaw

Ticker Report Rodman Renshaw assumed coverage on shares of Passage Bio (NASDAQ:PASG - Free Report) in a research note issued to investors on Tuesday morning, Marketbeat reports. The brokerage issued a buy...\n more…

Passage Bio initiated with bullish view at Rodman & Renshaw

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...\n more…

Vanguard Group Inc. Increases Stock Position in Passage Bio, Inc. (NASDAQ:PASG)

Ticker Report Vanguard Group Inc. boosted its holdings in Passage Bio, Inc. (NASDAQ:PASG - Free Report) by 2.6% in the 1st quarter, Holdings Channel reports. The firm owned 2,071,538 shares of the company's stock...\n more…

Passage Bio, Inc. (NASDAQ:PASG) Forecasted to Post Q3 2024 Earnings of ($0.17) Per Share

Ticker Report Passage Bio, Inc. (NASDAQ:PASG - Free Report) - Stock analysts at Wedbush upped their Q3 2024 earnings per share estimates for shares of Passage Bio in a research note issued on Thursday, August 8th...\n more…